Send me real-time posts from this site at my email

Why PLx Pharma Took Off Like a Rocket Today

What happened

Specialty pharmaceutical company PLx Pharma (NASDAQ: PLXP) had a day to remember on Tuesday, rising 27%. After market close on Monday, it revealed it had struck a deal with one of the top retailers on planet Earth.

So what

PLx Pharma's counterparty in the deal is Walmart (NYSE: WMT). The pharmaceutical company announced that its top product, the liquid aspirin capsule Vazalore, will be stocked in more than 4,500 Walmart stores throughout the U.S.

Image source: Getty Images.

The company won't have to wait long to start reaping the benefits of its Walmart presence; it said that three Vazalore offerings would start appearing on the retailer's shelves next month. The stores will stock 81-milligram capsules in 12- and 30-count containers, and shoppers can opt for a 325 milligram version in a 30-count package.

"With Walmart's broad reach and millions of customers, patients will have easy access to Vazalore in most of their stores nationwide," PLx Pharma CEO Natasha Giordano said in a statement. "Walmart's commitment is a real tribute to their recognition of Vazalore as an innovative aspirin therapy."

Now what

PLx Pharma is making quick and big strides with Vazalore. The product -- which is classified as a "drug delivery platform" because it neatly and safely transports liquid aspirin through the stomach to treat gastrointestinal difficulties -- received FDA approval for supplemental New Drug Applications (sNDAs) for the above-mentioned dosages in March.

A deal with such a major retailer this early in the game bodes very well for Vazalore's future. And, by extension, that of its maker.

10 stocks we like better than PLx Pharma Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and PLx Pharma Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 7, 2021

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue